title: Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury.
abstract: Clinical studies demonstrate that acute renal failure (ARF) is associated with increased mortality, which may be due to pulmonary complications. ARF may affect the lung via increased renal production or impaired clearance of mediators of lung injury, such as proinflammatory cytokines. Bilateral nephrectomy is a method to examine directly the deleterious systemic effects of absent renal clearance in ARF without the confounding effects that are associated with ischemia-reperfusion injury (e.g., ischemic ARF) or systemic toxicity (e.g., cisplatin-induced ARF). This study contrasts the effects of ischemic ARF and bilateral nephrectomy on serum cytokines and lung injury. It demonstrates that the acute absence of kidney function after both ischemic ARF and bilateral nephrectomy is associated with an increase in multiple serum cytokines, including IL-6 and IL-1beta, and that the cytokine profiles were distinct. Lung injury after ischemic ARF and bilateral nephrectomy was similar and was characterized by pulmonary vascular congestion and neutrophil infiltration. For investigation of the role of proinflammatory cytokines in pulmonary injury after ARF, the anti-inflammatory cytokine IL-10 was administered before bilateral nephrectomy. IL-10 treatment improved pulmonary architecture and was associated with a reduction in inflammatory markers, including bronchoalveolar lavage fluid total protein, pulmonary myeloperoxidase activity (a biochemical marker of neutrophils), and the chemokine macrophage inflammatory protein 2. These data demonstrate for the first time that the acute absence of kidney function results in pulmonary injury independent of renal ischemia and highlight the critical role of the kidney in the maintenance of serum cytokine balance and pulmonary homeostasis.
authors.affiliation: Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, CO80262, USA.
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Hoke
authors.forename: Ivor S
authors.initials: IS
authors.lastname: Douglas
authors.forename: Christina L
authors.initials: CL
authors.lastname: Klein
authors.forename: Zhibin
authors.initials: Z
authors.lastname: He
authors.forename: Wenfeng
authors.initials: W
authors.lastname: Fang
authors.forename: Joshua M
authors.initials: JM
authors.lastname: Thurman
authors.forename: Yunxia
authors.initials: Y
authors.lastname: Tao
authors.forename: Belda
authors.initials: B
authors.lastname: Dursun
authors.forename: Norbert F
authors.initials: NF
authors.lastname: Voelkel
authors.forename: Charles L
authors.initials: CL
authors.lastname: Edelstein
authors.forename: Sarah
authors.initials: S
authors.lastname: Faubel
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology*; D000818:Animals; D016207:Cytokines / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D018836:Inflammation Mediators / Q000378:metabolism; D016753:Interleukin-10 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology / Q000652:urine; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D055370:Lung Injury; D051379:Mice; D008810:Mice, Inbred C57BL; D009392:Nephrectomy / Q000009:adverse effects*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism
chemical_list: D016207:Cytokines; D018836:Inflammation Mediators; D015850:Interleukin-6; D012333:RNA, Messenger; D016753:Interleukin-10